Immunic

Immunic AG highlighted 2024 achievements, including progress in Phase 2 CALLIPER and Phase 3 ENSURE trials for vidofludimus calcium in multiple sclerosis, expecting top-line data by April 2025. Strengthened leadership and secured $240M in funding, extending cash runway to Q3 2025. Also advanced IMU-856 for gastrointestinal disorders.

Immunic, Inc. anticipates top-line data from the Phase 2 CALLIPER trial of vidofludimus calcium in progressive multiple sclerosis by April 2025. Positive interim analysis from Phase 3 ENSURE trials in relapsing multiple sclerosis supports continuation without changes. The company strengthened its team and secured up to $240 million in funding, extending its cash runway into 2025.

Immunic AG highlighted 2024 achievements, including progress in Phase 2 CALLIPER and Phase 3 ENSURE trials for vidofludimus calcium in multiple sclerosis, expecting top-line data in April. Strengthened management and secured up to $240M in funding. Published IMU-856 trial results in The Lancet Gastroenterology & Hepatology, showing potential in gastrointestinal disorders.

UNITY Biotechnology appoints Federico Grossi, M.D., Ph.D., as chief medical officer to advance its age-related disease treatments. Grossi's expertise in clinical development and regulatory strategy, especially in ophthalmology, is expected to boost UNITY's therapeutic portfolio, including the Phase 2b ASPIRE study of UBX1325 for diabetic macular edema.